Silexion Therapeutics (SLXN)

NasdaqMarket Closed

Silexion Therapeutics Corp is a clinical-stage biotechnology company developing oncology treatments for cancers associated with KRAS mutations. KRAS is one of the most frequently altered oncogenes in human cancer and has historically been difficult to target, making it an important area of research across pancreatic, colorectal, lung, and other solid tumour indications.

The company’s approach is based on RNA interference, using small interfering RNA, or siRNA, constructs intended to reduce production of mutant KRAS proteins. Rather than inhibiting a protein after it is made, Silexion’s technology is designed to interfere earlier in the disease pathway by prompting degradation of the messenger RNA that carries instructions from the mutated gene to the cell’s protein-making machinery. This mechanism is intended to limit the cancer-driving effects of KRAS mutations at the molecular level.

Silexion’s lead candidate, SIL204, is described as a second-generation siRNA therapy engineered to suppress mutated KRAS protein production. The company’s siRNA constructs are chemically modified with the aim of improving stability and cellular uptake while preserving biological activity. These properties are important for RNA-based medicines because delivery, durability, and target engagement can strongly influence therapeutic potential.

As an oncology-focused clinical-stage company, Silexion’s prospects depend on the progression of its research and clinical programmes, the strength of its intellectual property, access to capital, and evidence that its platform can translate into meaningful patient benefit. Its focus on KRAS places it in a competitive but medically significant field where new treatment options remain in demand.

0.45USD
0.45 USD
−0.58(-56.10%)
After-hours

Last updated

Market Cap
$2,073,078
P/E
P/FCF
P/S
Enterprise Value
Sector
Materials
Industry
Biological Products, Except Diagnostic Substances
Address
12 ABBA HILLEL ROAD, RAMAT GAN, L3, 5250606
Market Cap
$2,073,078
Enterprise Value
P/E
P/B
P/S
EV / EBITDA
EV / Sales
EPS
Dividend Yield
P/FCF
P/CF
Free Cash Flow
ROE
ROA
Debt / Equity
Current Ratio
Quick Ratio
Cash
Avg Volume
Fundamentals Snapshot Price

Financial statements are not available for this listing.

KindFilingDateLink
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar indexS-1/A — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar indexS-1 — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar indexDEFA14A — Silexion Therapeutics CorpView Filing
edgar indexSCHEDULE 13D/A — Silexion Therapeutics CorpView Filing
edgar index424B3 — Silexion Therapeutics CorpView Filing
edgar indexEFFECT — Silexion Therapeutics CorpView Filing
edgar indexDEF 14A — Silexion Therapeutics CorpView Filing
edgar indexS-3 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
form 4Form 4 — Hadar IlanView Filing
form 4Form 4 — Hadar IlanView Filing
form 4Form 4 — Horenshtein Hadar MiritView Filing
form 4Form 4 — Shirvan MitchellView Filing
form 4Form 4 — Shirvan MitchellView Filing
edgar indexPRE 14A — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar indexSCHEDULE 13D/A — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar indexS-8 — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar index10-K/A — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar indexSCHEDULE 13G/A — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar index10-Q — Silexion Therapeutics CorpView Filing
eight k text8-K — 8-KView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar indexEFFECT — Silexion Therapeutics CorpView Filing
edgar indexEFFECT — Silexion Therapeutics CorpView Filing
edgar indexPOS AM — Silexion Therapeutics CorpView Filing
edgar indexPOS AM — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar indexDEFA14A — Silexion Therapeutics CorpView Filing
edgar indexDEF 14A — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar indexPRE 14A — Silexion Therapeutics CorpView Filing
form 4Form 4 — Shirvan MitchellView Filing
form 4Form 4 — Shirvan MitchellView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar index8-K — Silexion Therapeutics CorpView Filing
edgar index10-K — Silexion Therapeutics CorpView Filing
edgar indexDRS — Silexion Therapeutics CorpView Filing
ten k section10-K — businessView Filing
ten k section10-K — mdaView Filing
ten k section10-K — risk_factorsView Filing
edgar indexDEFA14A — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar indexDEF 14A — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
edgar index4 — Silexion Therapeutics CorpView Filing
form 4Form 4 — Lushi AvnerView Filing